| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Feb 2026 | 30 Jan 2026 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended December 31 2025. 2. Limited Review Report for the quarter ended December 31 2025. 3. Any other business with the permission of the Chair. With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, at 12:00 noon at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH Act) w.e.f., 04.02.2026. (Attached as Annexure -I) (As per BSE Announcement dated on: 04.02.2026) | ||
| Board Meeting | 7 Nov 2025 | 3 Nov 2025 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 inter alia to consider and approve 1. Un-audited Financial results for the quarter and half year ended September 30 2025. 2. Limited Review Report for the quarter ended September 30 2025. 3. Any other business with the permission of the Chair. Outcome of the Board meeting held on 07.11.2025 (As Per Bse Announcement dated on 07/11/2025) | ||
| Board Meeting | 25 Aug 2025 | 25 Aug 2025 |
| Outcome of Board meeting held on 25.08.2025. | ||
| Board Meeting | 14 Aug 2025 | 11 Aug 2025 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended June 30 2025. 2. Limited Review Report for the quarter ended June 30 2025. 3. Any other business with the permission of the Chair. Outcome of Board Meeting for the Un-audited financial results for quarter ended 30.06.2025 and other matters under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on: 14.08.2025) | ||
| Board Meeting | 20 Jun 2025 | 20 Jun 2025 |
| We hereby attaching you the board meeting outcome | ||
| Board Meeting | 30 May 2025 | 26 May 2025 |
| Audited Results - Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the company will be held on Friday, May 30, 2025, inter alia, to consider the audited financial results of the Company for the Fourth quarter and Financial Year ended on March 31, 2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015. In continuation to our earlier intimation of closure of trading window, we would like to inform that the trading window of the Company for all the designated persons and their immediate relatives will remain closed till June 01, 2025, which is 48 hours after the said Board Meeting. Results For the Financial Year ended 31st March 2025 (As Per BSE Announcement Dated on: 30/05/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
